RU92016354A - Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата - Google Patents

Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата

Info

Publication number
RU92016354A
RU92016354A RU92016354/14A RU92016354A RU92016354A RU 92016354 A RU92016354 A RU 92016354A RU 92016354/14 A RU92016354/14 A RU 92016354/14A RU 92016354 A RU92016354 A RU 92016354A RU 92016354 A RU92016354 A RU 92016354A
Authority
RU
Russia
Prior art keywords
enhancing cytotoxic
immunotoxin
recurrence
conjugate
prevention
Prior art date
Application number
RU92016354/14A
Other languages
English (en)
Other versions
RU2119352C1 (ru
Inventor
М.Дж. Розенблюм
Original Assignee
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн
Priority claimed from PCT/US1991/002696 external-priority patent/WO1991016071A1/en
Publication of RU92016354A publication Critical patent/RU92016354A/ru
Application granted granted Critical
Publication of RU2119352C1 publication Critical patent/RU2119352C1/ru

Links

Claims (1)

  1. Композиция содержит иммуноконъюгаты антител, специфичных к антигену 240 кД, ассоциированному с опухолью меланомы. Цитотоксичные иммуноконъюгаты, такие, как конъюгаты антитела ZМЕ - 018, используются для лечения болезней пролиферативных клеток, таких, как меланома, а также других опухолей, несущих антиген ZМЕ-018. Различные помеченные составы применяют для диагностики таких заболеваний.
RU92016354A 1990-04-19 1991-04-19 Коньюгат антимеланомного антитела и цитотоксического агента и способ ингибирования меланомы RU2119352C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51092390A 1990-04-19 1990-04-19
US510923 1990-04-19
PCT/US1991/002696 WO1991016071A1 (en) 1990-04-19 1991-04-19 Antibody conjugates for treatment of neoplastic disease

Publications (2)

Publication Number Publication Date
RU92016354A true RU92016354A (ru) 1995-05-10
RU2119352C1 RU2119352C1 (ru) 1998-09-27

Family

ID=24032743

Family Applications (1)

Application Number Title Priority Date Filing Date
RU92016354A RU2119352C1 (ru) 1990-04-19 1991-04-19 Коньюгат антимеланомного антитела и цитотоксического агента и способ ингибирования меланомы

Country Status (23)

Country Link
US (1) US20050214307A1 (ru)
EP (1) EP0525119B1 (ru)
JP (1) JP3340127B2 (ru)
KR (1) KR100212372B1 (ru)
CN (1) CN1071579C (ru)
AT (1) ATE164078T1 (ru)
AU (1) AU650267B2 (ru)
CA (1) CA2079902C (ru)
DE (1) DE69129109T2 (ru)
DK (1) DK0525119T3 (ru)
ES (1) ES2113376T3 (ru)
FI (1) FI104234B (ru)
HK (1) HK1008418A1 (ru)
IE (1) IE62496B1 (ru)
IL (1) IL97776A (ru)
NO (1) NO317485B1 (ru)
NZ (1) NZ237688A (ru)
PT (1) PT97423B (ru)
RU (1) RU2119352C1 (ru)
SA (1) SA91120208B1 (ru)
TW (1) TW211573B (ru)
WO (1) WO1991016071A1 (ru)
ZA (1) ZA912490B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
ATE496066T1 (de) * 2002-10-25 2011-02-15 Us Gov Health & Human Serv Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta
AU2006210769A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US20070297983A1 (en) * 2006-03-16 2007-12-27 Soldano Ferrone Inhibition of breast carcinoma stem cell growth and metastasis
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
KR101641206B1 (ko) 2013-06-24 2016-07-22 에이비엘바이오 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
PL238187B1 (pl) * 2015-01-23 2021-07-19 Helix Biopharma Corp Koniugaty przeciwciało-ureaza dla celów terapeutycznych
US11458172B2 (en) 2017-09-08 2022-10-04 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
CN110455903A (zh) * 2018-05-07 2019-11-15 天士力生物医药股份有限公司 一种注射用重组人尿激酶原杂质分析的梯度电泳检测方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6306626B1 (en) * 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) * 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5513296A (en) * 1994-06-08 1996-04-30 Holmes Products Corp. Air heater with angled PTC heaters producing diverging heated airflow
AU3548799A (en) * 1998-04-03 1999-10-25 Invitrogen Corporation Libraries of expressible gene sequences
DE50112965D1 (de) * 2000-04-22 2007-10-18 Pharmedartis Gmbh Apoptotika
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Similar Documents

Publication Publication Date Title
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
ES2113376T3 (es) Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas.
HK1155070A1 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 -
ATE106750T1 (de) Funktionspezifische antikörper.
DE68928946T2 (de) Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
ES2120416T3 (es) Inhibidores del crecimiento tumoral derivados de tejidos, metodos de preparacion y usos de dichos inhibidores.
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
BR8905657A (pt) Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica
ES556684A0 (es) Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
FI924576A (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens
PT100660A (pt) Compostos conjugados uteis para o tratamento de tumores gastrointestinais e composicoes farmaceuticas que os contem